Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05046444Recruiting
Testing tricky blood cancer diagnoses with advanced DNA sequencing
This study uses advanced DNA sequencing to figure out unclear or unusual blood (hematologic) conditions when standard tests are not enough. It may help your care team reach a more accurate diagnosis by better understanding what’s driving your illness.
MunichAges 18–99 - NCT05041309Enrolling by invitation
Long-term follow-up after gene-modified cell treatment
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
Gilbert, ArizonaAges Any age - NCT05038722Enrolling by invitation
Testing how platelet transfusions work in people with low platelets
This study looks at platelet transfusions—how they’re used and whether platelets function well—for people with blood cancers who have low platelet counts. It may help improve transfusion care for people who need platelet support.
LinköpingAges 18 years+ - NCT05011045Recruiting
Brain radiation study tracking thinking and memory changes
This study looks at how whole-brain radiation affects thinking, memory, and other brain function in people with blood cancers that involve the brain. It may help doctors understand what to expect and which supportive treatments or monitoring could be useful.
Houston, TexasAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT04968834Recruiting
Collecting children’s and young adults’ blood and marrow for genetic testing
This study collects and stores blood and bone marrow samples from young people with certain blood cancers so doctors can do genetic (“genomic”) testing now and in the future. It may help improve understanding of the disease and support better matching of care for patients.
Hartford, ConnecticutAges Up to 30 years - NCT04888338Recruiting
Studying outcomes after CAR-T, radiation, or bispecific therapy
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Houston, TexasAges 18 years+ - NCT04448184RecruitingPhase 3
Platelet transfusion strategy during stem cell transplant
This trial compares how platelets are given during a stem cell transplant to help prevent bleeding. It also watches for clotting risks, since platelets can affect both bleeding and clot formation.
Calgary, AlbertaAges 18 years+ - NCT04640987RecruitingPhase 1
Stem cell transplant with added T-cells for blood cancers
This Phase 1 study tests a stem cell transplant plan that uses donor T-cells that have been specially processed and then added back. It aims to see if this approach is safer and works better for children and adults with serious blood cancers who need a transplant.
Palo Alto, CaliforniaAges 1 month–45 years - NCT04829136Recruiting
Fiber supplement for blood cancer treatment
This trial tests whether taking a daily fiber supplement can help people undergoing treatment for blood cancers. It aims to improve gut health and possibly reduce treatment side effects.
Seattle, WashingtonAges 18 years+ - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
Birmingham, AlabamaAges 18 years+ - NCT04671212Recruiting
Using discarded bone marrow from certain orthopedic surgeries
This study looks at bone marrow cells that would otherwise be discarded during some orthopedic surgeries. It may help researchers learn more about specific blood disorders (certain types of thalassemia and sickle cell–related conditions).
Memphis, TennesseeAges Any age - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT04450927Enrolling by invitation
Collecting health data from NHLBI patients and donors
This study collects information about standard care for people seen by the NHLBI, and also about donors. It helps researchers understand what happens in real-world care, which can improve future treatment decisions.
Bethesda, MarylandAges 2–120 - NCT04477681Recruiting
Expanded access to cancer medicines for young people who need options
This trial helps children, teens, and young adults get an innovative cancer medicine when their disease has returned or hasn’t responded—and standard options are not available. It checks whether a “compassionate use” or off-label medicine plan can be carried out safely for the people who need it.
Villejuif, Val de MarneAges Up to 25 years - NCT04266093Enrolling by invitation
Gene therapy follow-up for adults previously treated at NCI
This study is a follow-up check for people who were previously enrolled in certain NCI gene therapy treatment studies. It helps the research team monitor long-term effects and outcomes after treatment.
Bethesda, MarylandAges 18–120 - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+ - NCT04356469RecruitingPhase 2
Donor stem cell transplant for serious blood disorders in children
This trial tests a special type of donor stem cell transplant (with donor T-cells removed) to treat serious non-cancer blood problems in children. It may help by resetting the bone marrow so the body can make healthy blood cells again.
St. Petersburg, FloridaAges birth–21 years - NCT04237623RecruitingPhase 2
GM-CSF after transplant using a matched related donor
This Phase 2 study tests whether giving a medicine called GM-CSF after an allogeneic transplant (using a matched related donor) can improve outcomes. Participants must meet health and donor-matching requirements and be eligible to safely receive the treatment and consent to the study.
Atlanta, GeorgiaAges 18–78 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04202094Enrolling by invitation
Fertility options for young men after childhood cancer treatment
This study looks at fertility outcomes in young men who had cancer or blood disorders as children and then received high-risk treatment that can affect future fertility. It also compares people who did or did not store testicular tissue through a biopsy when they were younger.
BrusselsAges 18 years+ - NCT04208529Enrolling by invitationPhase 3
Long-term follow-up after receiving CTX001 infusion
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Palo Alto, CaliforniaAges 2 years+ - NCT03854318Recruiting
Study of families with suspected RUNX1 gene changes
This study follows people who have a known or suspected RUNX1 gene variant linked to FPDMM-like features. It may help improve understanding of the gene, and participants may contribute samples that researchers use for genetic testing and research.
Bethesda, MarylandAges 1 day–100 years - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Duarte, CaliforniaAges 12–78
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 575 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.